Cost effectiveness of LAA closure in patients with AF and contraindications to warfarin: comment

Europace. 2017 May 1;19(5):882. doi: 10.1093/europace/euw072.

Authors

Emilie P Belley-Côté^{1

2}, Iqbal Jaffer^{1

3}, André Lamy^{1

2}, Richard P Whitlock^{1

2}

Affiliations

¹ McMaster University, 237 Barton Street East, Hamilton, Ontario, Canada L8L 2X2.
² Population Health Research Institute, Hamilton, Ontario, Canada.
³ Thrombosis & Atherosclerosis Research Institute, Hamilton, Ontario, Canada.

PMID: 27194542
DOI: 10.1093/europace/euw072

No abstract available

Publication types

Letter
Comment

MeSH terms

Anticoagulants
Atrial Appendage
Atrial Fibrillation
Contraindications
Cost-Benefit Analysis*
Humans
Stroke
Warfarin*

Substances

Anticoagulants
Warfarin